Gynecology Oncology
Sharon Baisil; Rashmi Kundapur; Sachin Chandramoha; Maria Nelliyanil; Prince Abhraham; Vijith Shetty; Rajesh Ballal
Volume 7, Issue 3 , January and February 2022, , Pages 221-225
Abstract
Background and Objective: Breast cancer is the most common cancer among females globally and its toll is rapidly rising in India. Accurate knowledge about prognostic factors could assist oncologists in making correct treatment decisions and acquiring a better understanding of the survival of patients. ...
Read More
Background and Objective: Breast cancer is the most common cancer among females globally and its toll is rapidly rising in India. Accurate knowledge about prognostic factors could assist oncologists in making correct treatment decisions and acquiring a better understanding of the survival of patients. In patients with hormone receptor-positive, early diagnosis along with socioeconomic factors like education, income, etc., are said to play a vital role. Hence, the present study aimed to analyze the survival pattern depending on hormone receptor status, stages of breast cancer, and socioeconomic status.Methods: An Ambi directional cohort study was conducted among 300 patients with breast cancer registered and treated in a tertiary care hospital in Dakshina Kannada, India, in the last 3 years. A validated proforma was used to collect data. The post-treatment survival was analyzed depending on their income, family history, staging (clinical & histopathological), and hormone receptor status (HER-2/ER).Results: The pattern of receptor among these patients showed 45% ER, 43% PR, and 14.3% HER2 positivity. Among the patients, 83% had undergone hormonal therapy as per the receptor status. The overall survival rate of breast cancer patients was found to be 81%. The clinical stage of disease had a statistically significant association with survival using the log-rank test. However, monthly income and hormonal status showed no significance.Conclusion: A 3-year survival rate was 100% for stage Ⅰ patients, 96.6% for stage Ⅱ, 82.1% for stage Ⅲ, and 40% for stage Ⅳ. Hormone receptor positivity is highly predictive for better prognosis in breast cancer patients.